Aa
Best new treatments for GT 3A?
What are the most promising new drugs for GT 3A (interferon free)?
They should be filing soon. The stats on this MK 5172 + 3682 combo are amazingly good. Merck is busy working out their patient assistance program.
MK-3682 looks promising too. Anyone up to speed on that?
Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3 Infection (MK-3682-012)
https://clinicaltrials.gov/ct2/show/NCT02332720
Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3 Infection (MK-3682-012)
https://clinicaltrials.gov/ct2/show/NCT02332720
Thanks. Sounds like it is Daclatasvir and Sofosbuvir - article snips and link below.
Bristol-Myers Squibb Announces Acceptance of New Drug Application for Investigational Daclatasvir for FDA Review for the Treatment of Hepatitis C Genotype 3
The NDA contains data to support approval for daclatasvir in combination with sofosbuvir; would be the first 12-week regimen specifically for the treatment of hepatitis C genotype 3
The application is based on a Phase III clinical trial which tested a 12-week, ribavirin-free regimen and resulted in sustained virologic response (SVR12) in 90% of treatment-naïve and 86% of treatment-experienced genotype 3 HCV patients
Daclatasvir was approved in Europe in August 2014, and more recently in Brazil in January 2015, for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus (HCV) infection in adults.
http://news.bms.com/press-release/bristol-myers-squibb-announces-acceptance-new-drug-application-investigational-daclata
Bristol-Myers Squibb Announces Acceptance of New Drug Application for Investigational Daclatasvir for FDA Review for the Treatment of Hepatitis C Genotype 3
The NDA contains data to support approval for daclatasvir in combination with sofosbuvir; would be the first 12-week regimen specifically for the treatment of hepatitis C genotype 3
The application is based on a Phase III clinical trial which tested a 12-week, ribavirin-free regimen and resulted in sustained virologic response (SVR12) in 90% of treatment-naïve and 86% of treatment-experienced genotype 3 HCV patients
Daclatasvir was approved in Europe in August 2014, and more recently in Brazil in January 2015, for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus (HCV) infection in adults.
http://news.bms.com/press-release/bristol-myers-squibb-announces-acceptance-new-drug-application-investigational-daclata
BMS has just submitted for new drug approval and the FDA has accepted the request. My best guess is that it will be available for use with sovaldi in genotype 3 patients in the first quarter of 2016. There is about an 85%-90+% SVR rate in the trials.
Sof+dac therapy does not require ribavirin, but probably sof+dac is suboptimal for patients with cirrhosis...
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
